Psych Congress 2016

Asenapine Appears Effective Even in Advanced Pediatric Bipolar Disorder Progression

By October 23, 2016

Authors of a post-hoc analysis reported that asenapine is effective in the management of pediatric bipolar disorder regardless of the number of prior manic or mixed episodes.

Early Improvement With Vilazodone Might Predict Response, Remission in GAD

By October 23, 2016

Sufficient dosing and treatment duration might be needed to assess vilazodone's effectivness for management of symptoms among patients with GAD, concluded authors of a pooled analysis of data from three phase 3 clinical trials.

Oral to Injectable Tx Switch in Patients With Schizophrenia: An Analysis

By October 23, 2016

Study authors presented that most outpatients who started on aripiprazole lauroxil 882mg every 4 weeks remained for the entire year with completion rates ranging between 73.2% (oral aripiprazole) to 52.6% (oral olanzapine).

Paliperidone Palmitate vs. Oral Atypical Antipsychotics: Hospitalization, ER Visits Compared

By October 23, 2016

Among members of Humana's Medicare Advantage and Prescription Drug plan who have schizophrenia, paliperidone palmitate (PP) was associated with fewer hospitalizations and ER visits than oral atypical antipsychotics (OAAs), and the resulting healthcare system savings offset half of the cost difference between PP and OAAs.

Patient Assistance Program Might Help Boost Adherence to Antipsychotic LAIs

By October 23, 2016

Patient assistance programs might improve patient adherence with prescribed long-acting atypical antipsychotic injectables among people with schizophrenia, according to findings from a retrospective cohort study.

High-Dose Baclofen and Mania: What's the Link?

By October 23, 2016

Cases of baclofen-indued mania were seen in psychiatric patients receiving the drug for the mangement of tardive dyskinesia and alcohol dependence.

Does Adjunct Lurasidone to Lithium or Valproate Improve Bipolar I Disorder?

By October 23, 2016

Up to 20 weeks of treatment with lurasidone adjunctive to lithium or valproate in patients with bipolar I disorder resulted in a "clinically significant mean improvement in depression and mania scores" during the open-label stabilization phase of a randomized study.

Levomilnacipran ER Improves Functional Impairment, Cognition/Attention in MDD

By October 23, 2016

Levomilnacipran extended-release (ER) significantly improved overall symptoms of depression in patients with major depressive disorder (MDD) and cognitive difficulties.

Sertraline Overdose Leads to Case of SSRI-Induced Pancreatitis

By October 23, 2016

Does an overdose of a selective serotonin reuptake inhibitor (SSRI) increase risk of occurrence of pancreatitis?

Lurasidone Has Larger Effect on Schizophrenia Patients With Prominent Positive Symptoms

By October 23, 2016

Lurasidone was associated with medium to large treatment effect sizes in adult patients with schizophrenia who presented with prominent positive symptoms.

Do Psychostimulants Cause Inadequate Early Morning ADHD Symptoms Management?

By October 22, 2016

In online surveys, primary caregivers for children and adolescents on psychostimulant pharmacotherapy for ADHD reported that early morning hours were a time of inadequate symptom control, functional impairment, and parental stress.

Cariprazine Beneficial in Patients with Negative Symptoms of Schizophrenia

By October 22, 2016

Cariprazine "may provide benefit for negative symptoms in patients with schizophrenia," results from a pooled post hoc analysis have shown.

Lurasidone Significantly Lowers Odds of Mental Health-Related Hospitalizations

By October 22, 2016

Patients with bipolar disorder who received lurasidone monotherapy had "significantly lower odds of mental health-related hospitalizations" when compared with olanzapine, quetiapine, and risperidone monotherapy.

Urine Drug Tests May Help ID Antipsychotic Nonadherence, Substance Misuse

By October 22, 2016

Urine drug monitoring may help identify medication nonadherence and/or substance misuse, allowing early clinical intervention and improved therapeutic outcomes.

Brexpiprazole Maintenance Improves Psychosocial, Occupational Function in Schizophrenia

By October 22, 2016

Brexpiprazole is an 'efficacious' maintenance treatment for some patients with acute schizophrenia, improving and maintaining psychosocial and occupational functioning during a 52-week study, according to authors of a small study.

Vilazodone Significantly Reduces Depression Symptoms Across Subgroups of Adults

By October 22, 2016

Vilazodone may be an effective treatment option for adults with major depressive disorder (MDD) regardless of sex, age, MDD history, or baseline symptom severity.

Long-Acting Paliperidone Palmitate Inj Found to Up PANSS, PSP Scores in Schizophrenia

By October 22, 2016

Both paliperidone palmitate 1-month and 3-month long-acting injectables decreased the severity of symptoms and increased Personal and Social Performance (PSP) scale scores in patients with schizophrenia.

Updated Analysis Confirms Asenapine Dosing Efficacy in Bipolar I Disorder

By October 22, 2016

A new analysis updated to include data from a fixed-dose, randomized, placebo-controlled Phase 3 trial of asenapine treatment for bipolar disorder in adults supports a previously-reported numerically-superior effect on symptoms for twice-daily 10mg dosing over 5mg.

Extended-Release Oral Suspension for ADHD Effective, Well Tolerated in Children

By October 22, 2016

Amphetamine extended-release oral suspension was effective in reducing symptoms vs. placebo for the treatment of children aged 6-12 years with attention deficit/hyperactivity disorder (ADHD).